Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICAR30 in CD30-positive lymphomas
NCT03383965Phase 1Recruiting
- Start
- Mar 2017
- Primary completion
- Dec 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICAR30 in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). Primary endpoint: Safety of ICAR30 T cells at 2 years. Started Mar 2017; status: recruiting.
02
Drugs
ICAR30
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT03383965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383965.